Loading the session
Loading the session
Loading instrument
$77.97
−1.58%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:18 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −33.7% (SPY −1.6%, XLV +13.5%). 3 months: −28.4% (SPY −0.4%, XLV +15.5%). 1 year: +11.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CORT, SPY and XLV · as of 4 Nov 2026
8.6M shares were sold short at the 15 Oct 2026 settlement, 7.9% of the 108.1M shares outstanding; covering them would take 12.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 14-session relative strength index closed at 23.8 on 4 Nov 2026, its 9th session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
The 4 Nov 2026 close of $79.22 was 27.6% below its 50-day average ($109.43) and 5.0% above its 200-day average ($75.45). It has closed above the 200-day for 116 sessions, since 21 May 2026. The 50-day average crossed above the 200-day on 23 Jun 2026, 94 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $79.22 on 4 Nov 2026: 37.3% below the 52-week high of $126.38 (25 Aug 2026) and 176.4% above the low of $28.66 (19 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
July 30, 2026
+27.29%December 31, 2025
−50.42%March 31, 2025
+109.08%